EUVIMEDEUVIMED entdecken
Open Access

Preclinical Evaluation of 89Zr-Panitumumab for Biology-Guided Radiation Therapy

Arutselvan Natarajan, Syamantak Khan, Xuanwei Liang, Hieu Nguyen, Neeladrisingha Das, David Anders, Noeen Malik, Oluwaseyi M Oderinde, Frederick T Chin, Eben Rosenthal, Guillem Pratx

International Journal of Radiation Oncology*Biology*Physics · 2023

DOI: 10.1016/j.ijrobp.2023.01.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2023. Verfasst von Arutselvan Natarajan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Stanford University, Stanford, California. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Biology-guided radiation therapy (BgRT) uses real-time line-of-response data from on-board positron emission tomography (PET) detectors to guide beamlet delivery during therapeutic radiation. The current workflow requires 18F-fluorodeoxyglucose (FDG) administration daily before each treatment fraction. However, there are advantages to reducing the number of tracer injections by using a PET tracer with a longer decay time. In this context, we investigated 89Zr-panitumumab (89Zr-Pan), an antibody PET tracer with a half-life of 78 hours that can be imaged for up to 9 days using PET. METHODS AND MATERIALS: The BgRT workflow was evaluated preclinically in mouse colorectal cancer xenografts (HCT116) using small-animal positron emission tomography/computed tomography (PET/CT) for imaging and image-guided kilovoltage conformal irradiation for therapy. Mice (n = 5 per group) received 7 MBq of 89Zr-Pan as a single dose 2 weeks after tumor induction, with or without fractionated radiation therapy (RT; 6 × 6.6 Gy) to the tumor region. The mice were imaged longitudinally to assess the kinetics of the tracer over 9 days. PET images were then analyzed to determine the stability of the PET signal in irradiated tumors over time. RESULTS: Mice in the treatment group experienced complete tumor regression, whereas those in the control group were killed because of tumor burden. PET imaging of 89Zr-Pan showed well-delineated tumors with minimal background in both groups. On day 9 postinjection, tumor uptake of 89Zr-Pan was 7.2 ± 1.7 in the control group versus 5.2 ± 0.5 in the treatment group (mean percentage of injected dose per gram of tissue [%ID/g] ± SD; P = .07), both significantly higher than FDG uptake (1.1 ± 0.5 %ID/g) 1 hour postinjection. To assess BgRT feasibility, the clinical eligibility criteria was computed using human-equivalent uptake values that were extrapolated from preclinical PET data. Based on this semiquantitative analysis, BgRT may be feasible for 5 consecutive days after a single 740-MBq injection of 89Zr-Pan. CONCLUSIONS: This study indicates the potential of long-lived antibody-based PET tracers for guiding clinical BgRT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18HumansMiceAnimalsPanitumumabCell Line, TumorPositron-Emission TomographyBiology

Substanzen

PanitumumabFluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Radiology, Stanford University, Stanford, California.
  • Department of Radiation Oncology, Stanford University, Stanford, California.
  • Department of Physics, Foothill College, Los Altos, California.
  • RefleXion Medical, Inc, Hayward, California.
  • Department of Otolaryngology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Department of Radiation Oncology, Stanford University, Stanford, California. Electronic address: pratx@stanford.edu.

Förderung

  • NIH HHS

Zitieren

APA

Natarajan, A., Khan, S., Liang, X., Nguyen, H., Das, N., Anders, D., Malik, N., Oderinde, O. M., Chin, F. T., Rosenthal, E., & Pratx, G. (2023). Preclinical Evaluation of 89Zr-Panitumumab for Biology-Guided Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2023.01.007

Vancouver

Natarajan A, Khan S, Liang X, Nguyen H, Das N, Anders D, et al. Preclinical Evaluation of 89Zr-Panitumumab for Biology-Guided Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 2023. doi:10.1016/j.ijrobp.2023.01.007

BibTeX
@article{Natarajan2023,
  author = {Natarajan, Arutselvan and Khan, Syamantak and Liang, Xuanwei and Nguyen, Hieu and Das, Neeladrisingha and Anders, David and Malik, Noeen and Oderinde, Oluwaseyi M and Chin, Frederick T and Rosenthal, Eben and Pratx, Guillem},
  title = {Preclinical Evaluation of 89Zr-Panitumumab for Biology-Guided Radiation Therapy},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2023},
  doi = {10.1016/j.ijrobp.2023.01.007}
}
Kostenlos starten →